Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Let’s go ya low floating bastard
Spectaire Announces Strategic Distribution Partnership with a Fortune 1000 Energy Company
Where’s that Hindenburg group
Hahahahahahh they printed 90 bucks!!
Up large AH
PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness
Wake up
Who’s poking it
Pop
5 million block LOL
Amazing what happens when they turn on robots for the day
Uh oh
Buy high sell low
Watch out
Whether they take this to $10 plus itll be back to a toonie by summer
3 million more shares just traded in 3 mins!
62m in volume after a HUNDRED AND FIFTY reverse split
LOL
New highs
Don’t blink
The spread has varied once again from a penny to .25
More million dollar blocks being sold at a 500% premium to a month ago
What am I missing
Boing!
Yikes
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment
The fact they have this at a penny spread when they just did a 150-1 RS
just a printer full of ink
That leaky faucet….
Someone has been making a boat load here
RYVYL Inc. Announces Launch of Proposed Underwritten Public Offering
Like not legal
This is one manipulated ticker
What am I missing here
Why does this have T1 halt still?
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo